Glycotest Announces Start of Enrollment in Its Case-Control Study of the HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550).
Related News
Other posts that you should not miss.
New York, NY—November 21, 2019. Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company…
Glycotest Announces Start of Enrollment in Its Case-Control Study of the HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550). | Glycotest Diagnostics